. 2021 Dec 10;13(24):6225. doi: 10.3390/cancers13246225

Table 1.

Summary of clinical parameters and detected CTCs.

PID	Disease Status	Age (Years)	FIGO Stage	CA-125 (kU/L)	BRCA Status	Tumour PAX8	Treatment	Lymphovascular Involvement	CRS/Patient Outcome	Ascites (Volume)	CTC Count
OC 714	Recurrent	50	IIIC	114	WT	Positive	Surgery/AC	NR	NA	Absent	5
OC 1248	ND	71	IVA	354	WT	Positive	NACT	No	CRS 3	Large	0
OC 1251	ND	68	IIIC	1858	WT	Positive	NACT	Yes	CRS 2	Large	10
OC 1313	ND	55	IIIC	51	WT	Positive	NACT	Yes	CRS 1	Small	0
OC 1350	ND	72	IIIC	554	WT	Positive (Diffuse)	NACT	Yes	CRS 3	Small	0
OC 1354	ND	74	IIIC	169	WT	Positive	NACT	Yes	CRS 1	Absent	3
OC 1362	ND	68	IVA	1001	WT	Positive (Diffuse)	NACT	No	PD^1st	Absent	8
OC 1409	ND	66	IIIC	429	Mutant	Positive	NACT	Yes	CSR 2	Small	49
OC 1418	ND	73	IVB	1200	WT	Positive	NACT	Yes	CRS 2	Medium	0
OC 1423	ND	53	IVB	313	WT	Positive (Patchy)	NACT	No	CRS 2	Small	19
OC 1382	ND	68	IC	570	WT	NR	Surgery	Yes	Good	Small	41
OC 1388	Recurrent	79	IIIA	10	WT	Positive	Surgery/AC	NR	PD^†	NR	13
OC 1400	ND	65	IA #	27	WT	Negative	Surgery	No	Good	Absent	0
OC 1436	ND	82	IIIC	125	WT	Positive	Surgery	Yes	NA	Absent	2
OC 1458	ND	83	IVA	1056	WT	Positive	NACT	NR	PD^†a	Small	0
OC 1364	ND	58	IIIC	576	WT	NR	NACT	NR	PD^1st	NR	7

AC: Adjuvant chemotherapy; CRS: Chemotherapy response score; FIGO: International Federation of Gynaecology and Obstetrics; ND: Newly Diagnosed; # Mucinous borderline; NA: Not available; NR: Not reported; PD^1st: Progressive disease with first line NACT and patient was moved out of clinical trial; PD^†: Progressive disease after surgery and death of patient has ensued. PD^†a: Progressive disease with patient death occurring after 3rd round of NACT, thus, CRS was not done; WT: Wild type. Criteria for volume of ascites: Large volume (ascitic fluid > 1000 mL); medium volume (between 500 and 1000 mL); small volume (<500 mL).